KRAS and colorectal carcinoma: Small molecules that degrade both β-catenin and RAS while reducing EGFR transcription could thus be promising therapeutic candidates for the treatment of CRC, particularly CRCs resistant to EGFR-targeting treatments due to KRAS mutation [69].